Trial Profile
Phase II Randomized, Double Blind, Placebo Controlled, Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity Study in VLBW Neonates of BSYX-A110, for the Prevention of Staphylococcal Infection
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Jul 2022
Price :
$35
*
At a glance
- Drugs Pagibaximab (Primary)
- Indications Sepsis; Staphylococcal infections
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Biosynexus
- 17 Aug 2011 New trial record